

Accepted Manuscript

Safety, pharmacokinetics and efficacy of palifermin in children and adolescents with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium Trial

Joan Morris, MD, Mattias Rudebeck, MSc BMedSc, Steven Neudorf, MD, Theodore Moore, MD, Reggie Duerst, MD, Ami J. Shah, MD, Michael Graham, MD, Victor Aquino, MD, Christopher Morris, MD, Birgitta Olsson, MSc

PII: S1083-8791(16)00140-3

DOI: [10.1016/j.bbmt.2016.02.016](https://doi.org/10.1016/j.bbmt.2016.02.016)

Reference: YBBMT 54209


To appear in: *Biology of Blood and Marrow Transplantation*

Received Date: 28 December 2015

Accepted Date: 17 February 2016

Please cite this article as: Morris J, Rudebeck M, Neudorf S, Moore T, Duerst R, Shah AJ, Graham M, Aquino V, Morris C, Olsson B, Safety, pharmacokinetics and efficacy of palifermin in children and adolescents with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium Trial, *Biology of Blood and Marrow Transplantation* (2016), doi: 10.1016/j.bbmt.2016.02.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Safety, pharmacokinetics and efficacy of palifermin in children and adolescents with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium Trial

Joan Morris, MD¹; Mattias Rudebeck, MSc BMedSc²; Steven Neudorf, MD³; Theodore Moore, MD⁴; Reggie Duerst, MD⁵; Ami J Shah, MD⁶; Michael Graham, MD⁷; Victor Aquino, MD⁸; Christopher Morris, MD¹; Birgitta Olsson, MSc²

¹Pediatrics, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden; ³Cancer Institute, Children's Hospital of Orange County, CA, USA; ⁴Pediatrics, Mattel Children's Hospital UCLA, Los Angeles, CA, USA; ⁵Stem Cell Transplantation, Children's Memorial Medical Center, Chicago, IL, USA; ⁶Stem Cell Transplantation, Children's Hospital Los Angeles, CA, USA; ⁷Pediatrics Arizona Cancer Center, Tucson, AZ, USA; ⁸Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA

Correspondence and reprint requests: Mattias Rudebeck, Swedish Orphan Biovitrum, SE-112 76 Stockholm, Sweden. Fax: +46 8 697 23 30. Telephone: +46 8 697 22 36. E-mail: mattias.rudebeck@sobi.com.

Short title: Palifermin in pediatric patients with acute leukemias

Key words: palifermin, keratinocyte growth factor, pediatric, pharmacokinetics, safety

Financial Disclosure Statement: Rudebeck and Olsson are employees and shareholders of Sobi. J Morris and C Morris are currently employees of Amgen. Neudorf, Moore, Duerst, Shah, Graham, and Aquino report no financial or other conflict of interest relevant to the subject of this article.

Word count: Body: 3952; **Abstract:** 215

References: 39

Figures: 6 + 1 supplementary

Tables: 2

Download English Version:

<https://daneshyari.com/en/article/8430985>

Download Persian Version:

<https://daneshyari.com/article/8430985>

[Daneshyari.com](https://daneshyari.com)